Back to results
US 6,806,273 B1Granted
Compounds
AssigneeAstraZeneca AB
InventorsRupert Austin, Andrew Baxter, Roger Bonnert, Fraser Hunt, Elizabeth Kinchin, Paul Willis
Life of this patent
Estimating the term…
Abstract
The invention provides certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
Claims37
A compound of general formula
- wherein R1 represents a hydrogen atom, or a group —NR3R4;
- R3 and R4 each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl or C1-C8 alkyl group, which latter two groups are optionally substituted by one or more substituent groups independently selected from halogen atoms and —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, —SR10, —SO2R10, —SO2NR5R6, —NR8SO2R9, morpholinyl, C1-C4 alkyl, C3-C8 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group is optionally a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which is optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, —NR5R6, —CONR5R6, —OR7, —NR8COR9, —SO2NR5R6, —NR8SO2R9, C1-C6 alkyl and trifluoromethyl groups, or R3 and R4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system is optionally substituted by one or more substituent groups independently selected from
- —NR5R6, —CONR5R6, —OR7, —COOR10, —NR8COR9, and C1-C6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and —NR11R12 and —OR7 groups;
- X represents a group —OH or —NR13R14;
- R13 and R14 each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, C1-C8 alkyl, C2-C6 alkenyl or C2-C6 alkynyl group, which latter four groups are optionally substituted by one or more substituent groups independently selected from halogen atoms and —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, SR10, —SO2R10, —SO2NR5R6, —NR8SO2R9, morpholinyl, C1-C4 alkyl, C3-C6 cycloalkyl and aryl groups, wherein an aryl substituent group is optionally a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which is optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, —NR5R6, —CONR5R6, —OR7, —NR8COR9, —SO2NR5R6, NR8SO2R9, C1-C6 alkyl and trifluoromethyl groups,
- or R13 and R14 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system is optionally substituted by one or more substituent groups independently selected from —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, and C1-C6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and phenyl, —NR11R12 and —OR7 groups;
- R2 represents a C1-C6 alkyl or C2-C6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group is itself optionally substituted by one or more substituents independently selected from halogen atoms and nitro, C1-C6 alkyl, trifluoromethyl, —OR7, —C(O)R7, —SR10, —NR15R16 and phenyl groups;
- R5 and R6 each independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group, each of which is optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, —OR17 and —NR15R16, or R5 and R6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system is optionally substituted by one or more substituent groups independently selected from phenyl, —OR17—COOR17, —NR15R16, —CONR15R16, —NR15COR16, —SONR15R16, and C1-C6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and —NR15R16 and —OR17 groups;
- R7 and R9 each independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group, each of which is optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, —OR17 and —NR15R16;
- and
- each of R8, R10, R11, R12, R15, R16 and R17 independently represents a hydrogen atom or a C1-C6 alkyl or phenyl group;
- with the proviso that when R1 and X both represent —NH2, then R2 does not represent a methyl group;
- or a pharmaceutically acceptable salt or solvate or tautomer thereof.
10 more elements
An intermediate compound of formula (V);
- wherein L2 represents halogen and R2 represents a C1-C6 alkyl or C2-C6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group is itself optionally substituted by one or more substituents independently selected from halogen atoms and nitro, C1-C6 alkyl, trifluoromethyl, —OR7, C(O)R7, —SR10, —NR15R16 and phenyl groups, wherein R7 is a hydrogen atom or a C1-C6 alkyl or phenyl group which is optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, —OR17 and —NR15R16, wherein each of R10, R15, R16, and R17 independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group.
An intermediate compound of formula (VII)
- wherein L3 represents hydrogen, R2 represents a C1-C6 alkyl or C2-C6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group is itself optionally substituted by one or more substituents independently selected from halogen atoms and nitro, C1-C6 alkyl, trifluoromethyl, —OR7, C(O)R7, —SR10, —NR15R16 and phenyl groups, wherein R7 is a hydrogen atom or a C1-C6 alkyl or phenyl group which is optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, —OR17 and —NR15R16, wherein each of R10, R15, R16, and R17 independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group, and R3 and R4 each independently represent a hydrogen atom, or a 4-piperidinyl, C3-C6 cycloalkyl or C1-C8 alkyl group, which latter two groups are optionally substituted by one or more substituent groups independently selected from halogen atoms and —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, —SR10, —SO2R10, —SO2NR5R6, —NR8SO2R9, morpholinyl, C1-C4 alkyl, C3-C6 cycloalkyl, tetrahydrofuranyl and aryl groups, wherein an aryl substituent group may be a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, —NR5R6, —CONR5R6, —OR7, —NR8COR9, —SO2NR5R6, —NR8SO2R9, C1-C6 alkyl and trifluoromethyl groups, or R3 and R4 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system is optionally substituted by one or more substituent groups independently selected from
- —NR5R6, —CONR5R6, —OR7, —COOR10, —NR8COR9, and C1-C6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and —NR11R12 and —OR7 groups;
- X represents a group —OH or —NR13R14;
- R13 and R14 each independently represent a hydrogen atom, a 4-piperidinyl group optionally substituted by a C1-C4 alkylphenyl substituent group, or a C3-C7 carbocyclic, C1-C8 alkyl, C2-C6 alkenyl or C2-C6 alkynyl group, which latter four groups are optionally substituted by one or more substituent groups independently selected from halogen atoms and —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, —SR10, —SO2R10, —SO2NR15R6, —NR8SO2R9, morpholinyl, C1-C4 alkyl, C3-C6 cycloalkyl aryl groups, wherein an aryl substituent group is optionally a phenyl, naphthyl, thienyl, pyridinyl, imidazolyl or indolyl group, each of which is optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, —NR5R6, —CONR5R6, —OR7, —NR8COR9, —SO2NR5R6, NR8SO2R9, C1-C6 alkyl and trifluoromethyl groups,
- or R13 and R14 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system is optionally substituted by one or more substituent groups independently selected from —NR5R6, —CONR5R6, —OR7, —COOR7, —NR8COR9, and C1-C6 alkyl optionally substituted by one or more substituents independently selected from halogen atoms and phenyl, —NR11R12 and —OR7 groups.
2 more elements
An intermediate compound of formula (IX)
- wherein L4 is halogen, L5 is halogen and R2 represents a C1-C6 alkyl or C2-C6 alkenyl group optionally substituted by a phenyl or phenoxy group, wherein the phenyl or phenoxy group is itself optionally substituted by one or more substituents independently selected from halogen atoms and nitro, C1-C6 alkyl, trifluoromethyl, —OR7, C(O)R7, —SR10, —NR15R16 and phenyl groups, wherein R7 is a hydrogen atom or a C1-C6 alkyl or phenyl group which is optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, —OR17 and —NR15R16, wherein each of R10, R15, R16, and R17 independently represent a hydrogen atom or a C1-C6 alkyl or phenyl group.
Dependencies are inferred from the claim text.